Status: Recruiting
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).
Participants needed: 274
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Umoja BiopharmaUpdated: Oct 9, 2026Locations: 1
Eligibility criteria
18 years or older [+7]
Women who are pregnant or breastfeeding [+8]